177Lu-DOTA-AE105

N/A

Report date: 2025/11/20 16:04:44

NME

Base Information

Drug Name177Lu-DOTA-AE105

Drug Alias Name177Lu-DOTA-AE105177-Lu-DOTA-AE-105

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionPositron-emission tomography enhancersUrokinase plasminogen activator surface receptor inhibitors

TargetsUrokinase plasminogen activator surface receptor

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRigshospitalet

China Registration ClassN/A

Develop Information

Active CompaniesRigshospitalet

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A